At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed incurable primary mixed glioma that is recurrent or refractory after standard therapy including radiation
- ✓Evidence of recurrent or refractory tumor on MRI within two weeks before study entry
- ✓Tumor at least 5 mm in size
- ✓Age 18 and over
- ✕Prior antineoplaston therapy
- ✕Known chronic heart failure or history of congestive heart failure
- ✕Uncontrolled hypertension
- ✕Severe lung disease or severe chronic obstructive pulmonary disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Mixed Glioma
In Brief
A Phase 2 clinical trial evaluating Atengenal and Astugenal for Mixed Gliomas. Completed, enrolled 20 participants across 1 site.
Detailed Summary
RATIONALE: Current therapies for adults with recurrent or refractory mixed gliomas provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of adults with recurrent or refractory mixed gliomas. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on adults with recurrent or refractory mixed gliomas.
Study Details
Timeline
Interventions
Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).